Study reveals early death predictors in COVID-19 patients with cardiac injury

Announcing a new article publication for Cardiovascular Innovations and Applications journal. The activation of immune and thrombotic biomarkers at admission, and their ability to predict cardiac injury and mortality patterns in COVID-19, remains unclear.

Takeda’s FRUZAQLA gains approval in Japan for colorectal cancer

FRUZAQLA is intended for patients with CRC that has progressed following chemotherapy. Credit: SewCreamStudio/Shutterstock. Takeda has secured approval from the Japanese Ministry of Health, Labour

September 24, 2024

Codexis cuts 25% of staff, slashes drug programs while doubling down on RNAi tech

The enzyme engineering specialists at Codexis are giving up on making their own therapies, instead focusing on selling its technologies and services to customers —

July 22, 2023

Is a contrarian leader good for the FDA?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we have

December 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.